Jan. 18, 2011
The Tissue Engineering and Regenerative Medicine International Society (TERMIS) will partner with the Parker H. Petit Institute for Bioengineering and Bioscience at Georgia Tech in 2013 by hosting its annual North American Conference in Atlanta.
Two members of the Petit Institute’s faculty have been designated to head the 2013 TERMIS conference. The conference chair will be Robert E. Guldberg, Ph.D., the director of the Petit Institute and professor in mechanical engineering and the program chair will be Todd McDevitt, PhD, associate professor in biomedical engineering and the director of the Stem Cell Engineering Center at Georgia Tech.
“We are honored to be selected and look forward to putting on a great meeting,” Guldberg said. TERMIS brings together an international community to promote discussion of the scientific challenges and therapeutic benefits for the development and application of the tissue engineering and regenerative medicine fields. TERMIS’ mission is to promote worldwide science and technology advancement and education in these fields. It does so through regular worldwide conferences, publishing the Tissue Engineering journal that it endorses and providing quarterly newsletters and other communications for its members.
“Bob and I are dedicated to creating a dynamic program that will honor the meetings of the past as well as introduce some new elements,” McDevitt remarked. TERMIS has been evolving over the last decade. Its roots began in 2001 as an annual workshop called “Tissue Growth Engineering” that was organized by the Pittsburgh Tissue Engineering Initiative. In 2004, this small workshop evolved into the larger, national meeting called Regenerate. In 2006, the Regenerate World Congress was held in Pittsburgh where the meeting had grown significantly and had a large international following. By the following year, the society was rebranded into TERMIS to encompass its international presence. The society has continued to grow and now has chapters in Europe and Asia. TERMIS is open to anyone engaged in research in the tissue engineering or regenerative medicine arenas.
The 2011 TERMIS North American conference was held in Houston, Texas and in 2012 the entire society will come together for the TERMIS World Congress in Vienna, Austria.
News Contact
Megan McDevitt
IBB
Contact Megan McDevitt
404-385-7001
Sep. 23, 2010
Phillip Santangelo, assistant professor in the Coulter Department, has received an R01 NIH/National Institute for General Medicine Sciences award to develop single molecule sensitive probes for the study of virus replication, assembly and budding. The $1.48 million project will focus on the human respiratory syncytial (hRSV) virus. hRSV is recognized as the most important viral agent of serious pediatric respiratory tract disease. Worldwide, acute respiratory tract disease is the leading cause of mortality due to infectious disease, and hRSV remains one of the pathogens deemed most important for vaccine and antiviral development. He will collaborate with James E. Crowe, Jr., MD, The Departments of Microbiology and Immunology, and Pediatrics and The Vanderbilt Vaccine Center; Vanderbilt University Medical Center for the 5-year study.
News Contact
Adrianne ProellerWallace H. Coulter Dept. of Biomedical Engineering
Contact Adrianne Proeller
Sep. 24, 2010
Atlanta (September 24, 2010) — Assistant Professor Francesca Storici (Biology) has been awarded a research grant by the National Science Foundation (NSF) for a 3 year project focusing on “Mechanisms of RNA/DNA hybrid stability and of information flow from RNA to DNA in yeast cells". The goal of this research is to understand the mechanisms by which RNA can directly transfer information to the DNA of cells. The main objectives are: 1) to identify the main protein factors cleaving the RNA tract in an RNA/DNA hybrid during RNA-driven DNA repair and DNA modification and to characterize their in vivo functions, and 2) to reveal the role of DNA repair mechanisms in the removal of RNA embedded into DNA. This project addresses challenging questions in molecular biology: How likely is information flow from RNA to DNA in cells? How well is RNA tolerated in DNA? What are the consequences of RNA-driven modifications in cells? The study will be done using newly developed systems in the yeast Saccharomyces cerevisiae, which will be exploited to perform molecular and cellular biology experiments to identify and characterize the molecular mechanisms of RNA-driven DNA repair and editing.
Related Links
Sep. 20, 2010
Georgia Tech's largest graduate student organization, Bioengineering and Bioscience Unified Graduate Students (BBUGS), with the support of the Parker H. Petit Institute for Bioengineering and Bioscience (IBB), hosted its annual Buzz on Biotechnology High School Open House.
Open to all Atlanta area high school students, parents and teachers, this year's event drew a record 400+ attendees from 56 different schools. Visitors came to engage in a wide variety of hands-on, innovative science and engineering demonstrations such as "Edible Cells," "Virtual Stomach Surgery," "Acids and Bases," "Electromyography Recordings of Muscles," "Protein Folding." They were able to tour the state-of-the-art laboratories of IBB such as neuroengineering, robotics, atomic force microscopy and biomedical engineering labs. Many guests also attended bioengineering and stem cell seminars and even had the opportunity to take Georgia Tech campus tours and talk with an admissions representative.
The day wrapped up with the always-popular "Egg Drop" contest to find the safest, and lightest, "egg helmet" by dropping all those constructed throughout the day from the atrium's third floor.
The open house event was created in 2003 by BBUGS to reach out to area high school students to indulge their curiosity by introducing them to the world of science and engineering in a fun and accessible way.
News Contact
Colly Mitchell
Parker H. Petit Institute for Bioengineering and Bioscience
Contact Colly Mitchell
404-894-5982
Sep. 21, 2010
Essentially arrays of tiny test tubes, microplates have been used for decades to simultaneously test multiple samples for their responses to chemicals, living organisms or antibodies. Fluorescence or color changes in labels associated with compounds on the plates can signal the presence of particular proteins or gene sequences.
The researchers hope to replace these microplates with modern microelectronics technology, including disposable arrays containing thousands of electronic sensors connected to powerful signal processing circuitry. If they're successful, this new electronic biosensing platform could help realize the dream of personalized medicine by making possible real-time disease diagnosis - potentially in a physician's office - and by helping select individualized therapeutic approaches.
Aug. 31, 2010
Professor Greg Gibson (Biology) has received a 1 year pilot grant from the AFLAC Cancer Center for “Genomic profiling of late outcomes in survivors of childhood cancer". The study involves a collaboration with Drs. Ann Mertens and Karen Wasilewski in the Department of Hematology/Oncology at Emory University, and Dr. Ken Brigham, Director of the Center for Health Discovery and Well Being (CHDWB) at Emory. The objective of the project is to use a systems biology approach to try to understand why so many survivors of early childhood cancers begin to have a range of serious health problems as they reach adulthood, and to see if the CHDWB health care model might be an effective intervention. More information about the Emory childhood cancer survivor program can be found at http://www.choa.org/default.aspx?id=399
Sep. 01, 2010
Professors Wendy Kelly and Jake Soper both received Defense Advanced Research Projects Agency (DARPA) Young Faculty Awards. This program selects rising research stars from around the country and exposes them to the needs of the Department of Defense. DARPA’s goal is to fund researchers who will focus a significant portion of their careers on Department of Defense and National Security issues. Only 33 awards were made nationally in 2009, with two awarded to faculty in Georgia Tech’s School of Chemistry and Biochemistry. DARPA is funding Dr. Kelly’s research on “Biosynthetic engineering of thiopeptide antibiotics” and Dr. Soper’s research on “Redox-Active Ligand-Mediated Radical Coupling at Terminal Metal Oxo Ligands: Reactions Relevant to Water Oxidation for Artificial Photosynthesis”.
Sep. 01, 2010
Reproduction can be pressing business, fraught with challenges. But two University of Georgia scientists made a breakthrough discovery in reproduction and regeneration that has thrown open the doors to wide-ranging possibilities, including new therapies for devastating human diseases and the preservation of endangered animal species.
Steve Stice and Franklin West won what amounted to a hotly contested race to become the first scientists to produce induced pluripotent stem (iPS) cells from adult livestock
Aug. 24, 2010
Eva Lee Joins Interdisciplinary Team at Emory's New Center for Systems Vaccinology
Eva K. Lee, professor in the H. Milton Stewart School of Industrial and Systems Engineering at Georgia Tech and director of the Center for Operations Research in Medicine and HealthCare, joins a highly integrated and interdisciplinary team conducting research in the newly established Center for Systems Vaccinology at Emory University.
The National Institute of Allergy and Infectious Diseases of the National Institutes of Health awarded a five-year, $15.5 million grant to the Emory Vaccine Center at Yerkes National Primate Research Center in Atlanta. Scientists in the new Center will employ the modern analytic tools of systems biology to understand the immune responses vaccines stimulate in humans and will use this knowledge to guide design of vaccines against HIV, malaria and other global pandemics
Bali Pulendran, the Charles Howard Candler professor in the Department of Pathology and Laboratory Medicine at Emory University, the Emory Vaccine Center, and Yerkes Research Center, is principal investigator of the center. Rafi Ahmed, director of the Emory Vaccine Center and a Georgia Research Alliance Eminent Scholar, will serve as co-principal investigator.
Lee and other researchers at the center will address a major challenge thus far in the development of vaccines - that the effectiveness of vaccination can only be ascertained after vaccinated individuals have been exposed to infection. To study vaccine-induced immunity in humans, they will use a multidisciplinary approach Pulendran developed, which involves immunology, genomics and bioinformatics to predict the immunity of a vaccine without exposing individuals to infection.
Researchers working in the new Center for Systems Vaccinology will determine whether Pulendran's approach can be used to predict the effectiveness of other vaccines, including common vaccines against influenza, pneumococcal disease and shingles. The ability to successfully predict the immunity and efficacy of vaccines would facilitate the rapid evaluation of new and emerging vaccines and the identification of individuals who are unlikely to be protected by a vaccine.
The team's initial work will focus on two major projects on innate immunity and adaptive immunity that ultimately will facilitate vaccine development in several ways: (1) by enabling a strategy to prospectively predict the immunogenicity of vaccines; (2) by offering new and fundamental insights into the genes, cells and networks that orchestrate vaccine-induced immunity in the young and elderly; and (3) by facilitating the generation of an open access database of vaccine-induced molecular signatures.
The Center's interdisciplinary team comprises researchers and clinicians in areas as diverse as immunology, vaccinology, clinical medicine, computational modeling, and mathematics. In addition to Lee, the team includes Nick Haining (Dana Farber Cancer Institute, Boston), Shankar Subramaniam (University of California, San Diego), Alex Sette (La Jolla Institute for Allergy and Immunology, La Jolla), Mark Mulligan (Hope Clinic, Emory Vaccine Center,; and Myron Levine and Adriana Weinberg (University of Colorado, Denver).
Lee, along with Haining and Subramaniam, co-direct the "Genomics and Computational Biology" core of the initiative. The Core will provide expertise, analysis, and experimental platforms to systematically interrogate the immune response to the inactivated trivalent influenza vaccine, the pneumococcal polysaccharide vaccine, and the live attenuated varicella-zoster vaccine. Two major goals in this Core involve development of gene expression-based predictors of vaccine response in humans and use of genomic techniques as discovery tools to better understand the innate and adaptive immune response to vaccines.
Support for the first year of the Center initiative will come from the American Recovery and Reinvestment Act (ARRA).
News Contact
Barbara ChristopherIndustrial and Systems Engineering
Contact Barbara Christopher
404.385.3102
Aug. 18, 2010
Researchers have developed an improved coating technique that could strengthen the connection between titanium joint-replacement implants and a patient's own bone. The stronger connection - created by manipulating signals the body's own cells use to encourage growth - could allow the implants to last longer.
Implants coated with "flower bouquet" clusters of an engineered protein that mimics the body's own cell-adhesion material fibronectin made 50 percent more contact with the surrounding bone than implants coated with protein pairs or individual strands. The cluster-coated implants were fixed in place more than twice as securely as plugs made from bare titanium - which is how joints are currently attached.
Researchers believe the biologically-inspired material improves bone growth around the implant and strengthens the attachment and integration of the implant to the bone. This work also shows for the first time that biomaterials presenting biological sequences clustered together at the nanoscale enhance cell adhesion signals. These enhanced signals result in higher levels of bone cell differentiation in human stem cells and promote better integration of biomaterial implants into bone.
"By clustering the engineered fibronectin pieces together, we were able to create an amplified signal for attracting integrins, receptors that attached to the fibronectin and directed and enhanced bone formation around the implant," said Andres Garcia, professor in Georgia Tech's Woodruff School of Mechanical Engineering and the Petit Institute for Bioengineering and Bioscience.
Details of the new coating were reported in the August 18 issue of the journal Science Translational Medicine. The research was supported by the National Institutes of Health, the Arthritis Foundation, and the Atlanta Clinical and Translational Science Institute through the Georgia Tech/Emory Center for the Engineering of Living Tissues.
Total knee and hip replacements typically last about 15 years until the components wear down or loosen. For many younger patients, this means a second surgery to replace the first artificial joint. With approximately 40 percent of the 712,000 total hip and knee replacements in the United States in 2004 performed on younger patients 45-64 years old, improving the lifetime of the titanium joints and creating a better connection with the bone becomes extremely important.
In this study, Georgia Tech School of Chemistry and Biochemistry professor David Collard and his students coated clinical-grade titanium with a high density of polymer strands - akin to the bristles on a toothbrush. Then, Garcia and Tim Petrie - formerly a graduate student at Georgia Tech and currently a postdoctoral fellow at the University of Washington - modified the polymer to create three or five self-assembled tethered clusters of the engineered fibronectin, which contained the arginine-glycine-aspartic acid (RGD)sequence to which integrins binds.
To evaluate the in vivo performance of the coated titanium in bone healing, the researchers drilled two-millimeter circular holes into a rat's tibia bone and pressed tiny clinical-grade titanium cylinders into the holes. The research team tested coatings that included individual strands, pairs, three-strand clusters and five-strand clusters of the engineered fibronectin protein.
"To investigate the function of these surfaces in promoting bone growth, we quantified osseointegration, or the growth of bone around the implant and strength of the attachment of the implant to the bone," explained Garcia, who is also a Woodruff Faculty Fellow at Georgia Tech.
Analysis of the bone-implant interface four weeks later revealed a 50 percent enhancement in the amount of contact between the bone and implants coated with three- or five-strand tethered clusters compared to implants coated with single strands. The experiments also revealed a 75 percent increase in the contact of the three- and five-strand clusters compared to the current clinical standard for replacement-joint implants, which is uncoated titanium.
The researchers also tested the fixation of the implants by measuring the amount of force required to pull the implants out of the bone. Implants coated with three- and five-strand tethered clusters of the engineered fibronectin fragment displayed 250 percent higher mechanical fixation over the individual strand and pairs coatings and a 400 percent improvement compared to the unmodified polymer coating. The three- and five-cluster coatings also exhibited a twofold enhancement in pullout strength compared to uncoated titanium.
Georgia Tech bioengineering graduate students Ted Lee and David Dumbauld, chemistry graduate students Subodh Jagtap and Jenny Raynor, and research technician Kellie Templeman also contributed to this study.
This work was partly funded by Grant No. R01 EB004496-01 from the National Institutes of Health (NIH) and PHS Grant UL1 RR025008 from the Clinical and Translational Science Award program, NIH, National Center for Research Resources. The content is solely the responsibility of the principal investigator and does not necessarily represent the official view of the NIH.
News Contact
Abby Vogel RobinsonResearch News and Publications
Contact Abby Vogel Robinson
404-385-3364
Pagination
- Previous page
- Page 13
- Next page